5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

Nov. 8

Weekly Gain

AK Steel  (NYSE: AKS  )

$5.38

17%

Geron  (NASDAQ: GERN  )

$4.61

17%

Universal Display  (NASDAQ: OLED  )

$36.61

16%

3D Systems  (NYSE: DDD  )

$70.40

12%

Organovo  (NYSEMKT: ONVO  )

$8.20

10%

Source: Barron's.

Let's start with AK Steel. The producer of flat-rolled carbon, stainless, and electrical steels moved higher after jacking up its prices. AK Steel announced that the current spot market base prices for all of its carbon flat-rolled steel products will increase by $30 per ton. That will improve the company's margins.

Geron moved sharply higher after an abstract posted online showed promising results for its potentially promising myelofibrosis treatment. In a Mayo Clinic study, five of 18 patients in the abstract analysis achieved at least partial remission. The stock had more than doubled at one point, but it gave back most of those gains as the initial euphoric response settled. 

Universal Display lit up the room after posting better-than-expected financial results. It also boosted its outlook. The company has come under fire in the past on concerns that it may lose Samsung as its flagship customer, but the OLED technologist still managed to earn three times as much as Wall Street was forecasting.

3D Systems moved higher as Bloomberg reported on takeover speculation. The company stands out as a leader -- and profitable player -- in 3-D printing. A 3D Systems spokeswoman is quoted in the Bloomberg report, saying that the 3-D printing speedster is "not currently in discussions regarding an acquisition of the company's shares." However, the denial did little to suppress investor demand in the stock.

Finally we have Organovo on the move. This is the third consecutive week that Organovo has cranked out a 10% return. You're not going to see that happen too often. Organovo's goal is ambitious. It wants to give 3-D printing a medical turn, creating a proxy for human tissue that could be used to speed up treatment testing. Organovo's solution may be years away, but it's easy to fathom how popular Organovo will be if it does become the first to market this technology.

Keep the good vibes coming
Tired of watching your stocks creep up year after year at a glacial pace? Motley Fool co-founder David Gardner, founder of the world's No. 1 growth-stock newsletter, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, with you! It's a special 100% free report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains, and click here for instant access to a whole new game plan of stock picks to help power your portfolio.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2720433, ~/Articles/ArticleHandler.aspx, 8/28/2014 3:14:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement